SRPT - サレプタ・セラピュ―ティックス (Sarepta Therapeutics Inc.)

SRPTのニュース

   Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating  2022/04/07 20:04:00 Investor''s Business Daily
Sarepta Therapeutics sees its Relative Strength Rating reach the 80-plus level.
   VivoSense, which develops wearable biometric sensors to collect and organize data from patients for clinical drug trials, raises a $25M Series A (Keerthi Vedantam/dot.LA)  2022/03/31 03:55:01 Techmeme
Keerthi Vedantam / dot.LA : VivoSense, which develops wearable biometric sensors to collect and organize data from patients for clinical drug trials, raises a $25M Series A — As the CEO of Sarepta Therapeutics from 2011 to 2015, Chris Garabedian led a biotech firm striving to find cures for rare diseases.
   Morgan Stanley projects about a third of biotechs will need financing in 2022  2022/03/26 16:00:28 Kwhen Finance
   Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program  2022/03/08 13:30:00 GlobeNewswire
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 15 individuals living with Duchenne. Additionally, for the 2022-2023 school year, the program has been expanded and Sarepta will be awarding up to 5 academic scholarships of $5,000 to siblings of individuals living with Duchenne.
   Sarepta Therapeutics to Present at Upcoming Investor Conferences  2022/03/02 21:30:00 GlobeNewswire
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:
   Balyasny Asset Management LLC Sells 96,518 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)  2021/11/05 16:26:50 Transcript Daily
Balyasny Asset Management LLC trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 37.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,389 shares of the biotechnology companys stock after selling 96,518 shares during the period. Balyasny Asset Management LLC []
   Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $145.00 at Royal Bank of Canada  2021/11/04 13:54:41 Transcript Daily
Sarepta Therapeutics (NASDAQ:SRPT) had its price objective cut by investment analysts at Royal Bank of Canada from $148.00 to $145.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an outperform rating on the biotechnology companys stock. Royal Bank of Canadas target price indicates a potential upside of 67.57% []
   Berenberg Bank Stick to Their Hold Rating for Sarepta Therapeutics By Investing.com  2021/11/04 09:55:45 Investing.com
Berenberg Bank Stick to Their Hold Rating for Sarepta Therapeutics
   Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2021 Results - Earnings Call Transcript  2021/11/04 06:28:04 Seeking Alpha
   Sarepta Therapeutics EPS beats by $1.37, beats on revenue, raises product guidance  2021/11/03 20:09:24 Seeking Alpha
   Sarepta Therapeutics Inc (SRPT): Price Now Near $68.32; Daily Chart Shows Downtrend on 20 Day Basis  2021/07/16 15:14:16 ETF Daily News
The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Sarepta Therapeutics Inc (SRPT): Price Now Near $68.32; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   Limb Girdle Muscular Dystrophy (LGMD) Market 2021 | Covid19 Impact Analysis | Size, Share, Sales and Forecast to 2026: Sarepta Therapeutics, aTyr Pharma, Myonexus Therapeutics, .. , , etc.  2021/07/09 11:10:53 Tramways Monthly
Global Limb Girdle Muscular Dystrophy (LGMD) Market 2021 report is comprised of an in-depth analysis of the global industry which aims to deliver comprehensive market intelligence study associated with major market components. The report includes an overview of these markets on different fronts such as market size, market share, market penetration of the product and []
   Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)  2021/07/06 13:48:39 Insider Monkey
   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/06/30 22:40:58 Benzinga
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta''s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 2,450 shares of Sarepta''s common stock, and in the aggregate 1,250 restricted stock units ("RSUs"). The options have an exercise price of $77.74 per share, which is equal to the closing price of Sarepta''s common stock on June 30, 2021 Full story available on Benzinga.com

calendar